Serum Fibroblast Growth Factor 21 as a Novel Biomarker in Prediction of Coronary Artery Disease Severity

Khalaf, Mervat M.; Fayez, Salwa; Azouz, Taha

doi:10.9734/bjmmr/2016/29581

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…High serum FGF21 levels have been shown in obese patients with type 2 diabetes mellitus and metabolic syndrome [8] . Although the relationship between FGF21 and CVD has been shown in some studies, its role in the pathophysiology of CAD is still not fully understood [9] . We aimed to investigate the role of FGF21 in CAD development and CAD severity in patients with SAP.…”

Section: Introductionmentioning

confidence: 99%

Is serum fibroblast growth factor 21 associated with the severity or presence of coronary artery disease?

Nar¹,

Sanlialp²,

Nar³

et al. 2022

J Med Biochemistry

View full text Add to dashboard Cite

Aim: Recent studies have shown that increased circulating concentrations of fibroblast growth factor 21 (FGF21) are associated with obesity, metabolic disorder, and atherosclerosis. However, the studies which investigate the relationship between serum FGF21 levels and coronary artery disease (CAD) include conflicting data. In this study, we planned to investigate the role of FGF21 in CAD development and CAD severity. Method: Seventy-eight patients with stable angina pectoris (SA) (lesion positive) and 40 control patients (lesion negative) with similar cardiovascular risk factors who underwent coronary angiography were included in the study. Serum FGF21 levels were measured by ELISA method. CAD severity was evaluated by using SYNTAX and GENSINI risk scores. Results: Although there was a statistically significant difference between serum FGF21 levels in the SA and the control groups [101.18 ± 141.62 vs. 47.93 ± 58.74 pg/mL; p = 0.03], no correlation was found between the SYNTAX (r = 0.146 and p = 0.134) and GENSINI (r = 0.211 and p = 0.084) scores with serum FGF21 levels. The SA group had lower serum HDL-C levels (41.57 ± 11.40 vs. 54.90 ± 34.47; p = 0.02). There was a significant and negative relationship between serum FGF21 and serum HDL-C levels in correlation analysis (r = - 0.272; p = 0.026). Conclusion: The serum FGF21 levels are different between SA diagnosed and control patients. FGF21 may be a marker for CAD diagnosis, but not for the evaluation of CAD severity. To the best of our knowledge, this is the first study to evaluate coronary artery disease severity together with a lipid profile.

show abstract

Section: Introductionmentioning

confidence: 99%